US 12,453,737 B2
Method for hydrating lyophilized cyclophosphamide composition and product thereof
Hongzhen Yu, Shanghai (CN); Ziqiang Li, Shanghai (CN); Jiansheng Wan, Shanghai (CN); and Xiaoxi Sheng, Shanghai (CN)
Assigned to Sinotherapeutics Inc., Shanghai (CN); and Andorra Pharmaceuticals, LLC, Ocala, FL (US)
Appl. No. 17/265,678
Filed by Sinotherapeutics Inc., Shanghai (CN)
PCT Filed Aug. 5, 2019, PCT No. PCT/CN2019/099251
§ 371(c)(1), (2) Date Feb. 3, 2021,
PCT Pub. No. WO2020/025069, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 201810875707.5 (CN), filed on Aug. 3, 2018; and application No. 201811367499.4 (CN), filed on Nov. 16, 2018.
Prior Publication US 2022/0133754 A1, May 5, 2022
Int. Cl. A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01)] 18 Claims
OG exemplary drawing
 
1. An injectable composition, comprising cyclophosphamide and mannitol,
wherein the porosity of the composition is greater than 96%, and
the composition has a moisture content of 7.8% to about 9.0%, based on cyclophosphamide monohydrate.